Aeglea BioTherapeutics, Inc.
Hedge Funds Holdings
Last updated:
Aeglea BioTherapeutics, Inc.‘s stocks are currently a part of 21 hedge funds’ portfolios, which represents 9.45% of the total amount of its stocks outstanding. This makes up a total of 7.96M shares of Aeglea BioTherapeutics, Inc.. Compared to the previous quarter, the number fell by -81.34% or -34.70M shares fewer. As for the holding position changes, 28.57% (6) of current hedge fund investors increased the number of shares held, 23.81% (5) of current holders sold a part of the shares held, and 14.29% (3) closed the holdings completely. 2 hedge funds are new holders of Aeglea BioTherapeutics, Inc. stock in Q1 2023, it is 9.52% of total holders.
Hedge funds holding Aeglea BioTherapeutics (Q2 2018 – Q1 2023)
| Q2 2018 | 64 |
|---|---|
| Q3 2018 | 59 |
| Q4 2018 | 60 |
| Q1 2019 | 71 |
| Q2 2019 | 77 |
| Q3 2019 | 71 |
| Q4 2019 | 67 |
| Q1 2020 | 68 |
| Q2 2020 | 86 |
| Q3 2020 | 92 |
| Q4 2020 | 90 |
| Q1 2021 | 84 |
| Q2 2021 | 78 |
| Q3 2021 | 76 |
| Q4 2021 | 83 |
| Q1 2022 | 78 |
| Q2 2022 | 59 |
| Q3 2022 | 50 |
| Q4 2022 | 48 |
| Q1 2023 | 21 |
Hedge funds changes in Aeglea BioTherapeutics positions (Q2 2018 – Q1 2023)
| Q2 2018 | 32 | 22 | 4 | 6 | 0 |
|---|---|---|---|---|---|
| Q3 2018 | 9 | 22 | 17 | 14 | -3 |
| Q4 2018 | 10 | 18 | 16 | 9 | 7 |
| Q1 2019 | 17 | 25 | 12 | 6 | 11 |
| Q2 2019 | 16 | 35 | 9 | 8 | 9 |
| Q3 2019 | 6 | 24 | 22 | 11 | 8 |
| Q4 2019 | 7 | 21 | 16 | 12 | 11 |
| Q1 2020 | 9 | 22 | 21 | 7 | 9 |
| Q2 2020 | 26 | 42 | 13 | 8 | -3 |
| Q3 2020 | 17 | 23 | 30 | 11 | 11 |
| Q4 2020 | 10 | 32 | 28 | 12 | 8 |
| Q1 2021 | 3 | 23 | 33 | 9 | 16 |
| Q2 2021 | 3 | 29 | 26 | 9 | 11 |
| Q3 2021 | 9 | 24 | 23 | 10 | 10 |
| Q4 2021 | 17 | 26 | 22 | 10 | 8 |
| Q1 2022 | 8 | 28 | 24 | 13 | 5 |
| Q2 2022 | 13 | 19 | 15 | 30 | -18 |
| Q3 2022 | 4 | 9 | 13 | 13 | 11 |
| Q4 2022 | 9 | 12 | 9 | 11 | 7 |
| Q1 2023 | 2 | 6 | 5 | 3 | 5 |
Hedge funds changes in Aeglea BioTherapeutics stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 0 | 0 |
|---|---|---|
| Q3 2018 | 0 | 0 |
| Q4 2018 | 0 | 0 |
| Q1 2019 | 0 | 0 |
| Q2 2019 | 0 | 1,000 |
| Q3 2019 | 19,000 | 1,000 |
| Q4 2019 | 0 | 0 |
| Q1 2020 | 0 | 0 |
| Q2 2020 | 0 | 0 |
| Q3 2020 | 1,000 | 0 |
| Q4 2020 | 2,000 | 551,000 |
| Q1 2021 | 340,000 | 119,000 |
| Q2 2021 | 316,000 | 104,000 |
| Q3 2021 | 90,000 | 0 |
| Q4 2021 | 192,000 | 248,000 |
| Q1 2022 | 3,000 | 0 |
| Q2 2022 | 23,000 | 0 |
| Q3 2022 | 8,000 | 0 |
| Q4 2022 | 11,383 | 225 |
| Q1 2023 | 0 | 145,000 |